A high proportion of patients with relapsed classical Hodgkin's lymphoma achieve a response with the antibody-drug conjugate brentuximab vedotin, and the drug is well tolerated. We modified the escalated BEACOPP regimen (eBEACOPP; bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and implemented brentuximab vedotin with the aim to reduce toxic effects while maintaining the protocol's efficacy.

中文翻译：

---

将brentuximab vedotin纳入一线治疗晚期经典霍奇金淋巴瘤：德国霍奇金研究小组对一项2期随机试验的最终分析。

很大一部分复发的经典霍奇金淋巴瘤患者可通过抗体-药物结合物brentuximab vedotin产生应答，并且该药物具有良好的耐受性。我们修改了逐步升级的BEACOPP方案（eBEACOPP；博来霉素，依托泊苷，阿霉素，环磷酰胺，长春新碱，普卡巴嗪和泼尼松），并实施了brentuximab vedotin，目的是在维持方案疗效的同时降低毒性作用。